Crinetics Pharmaceuticals logo
CRNXCrinetics Pharmaceuticals
Trade CRNX now
Crinetics Pharmaceuticals primary media

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals (NASDAQ:CRNX) focuses on discovering, developing, and commercializing innovative treatments for endocrine diseases and endocrine-related tumors. The company is rigorously working on a diverse pipeline of product candidates aimed at addressing unmet medical needs in conditions such as acromegaly, Cushing's disease, and congenital hyperinsulinism through nonpeptide, orally available therapeutics. With a deep commitment to science and patient care, Crinetics Pharmaceuticals is dedicated to advancing new therapies that can significantly improve the lives of those battling endocrine conditions. Their objective is to lead the way in endocrine disease management by providing patients with more effective and convenient treatment options.

What is CRNX known for?

Snapshot

Public US
Ownership
2008
Year founded
269
Employees
San Diego, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
San Diego, US

Products and/or services of Crinetics Pharmaceuticals

  • Paltusotine, a nonpeptide somatostatin receptor agonist targeting acromegaly and neuroendocrine tumors.
  • CRN04777, an oral somatostatin receptor type 5 agonist for congenital hyperinsulinism.
  • CRN04894, an adrenocorticotropic hormone antagonist for Cushing's disease.
  • CRN01941, an oral nonpeptide somatostatin receptor type 2 biased agonist for acromegaly.
  • Development of therapies for hyperparathyroidism, focusing on calcium sensing receptor agonists.
  • Exploration of novel treatments for rare endocrine diseases, including those affecting the thyroid and adrenal glands.

Crinetics Pharmaceuticals executive team

  • Dr. R. Scott Struthers Ph.D.Founder, President, CEO & Director
  • Dr. Stephen F. Betz Ph.D.Co-Founder & Chief Scientific Officer
  • Mr. Jeff E. Knight M.P.H.Chief Development & Operating Officer
  • Mr. Tobin C. SchilkeChief Financial Officer
  • Ms. Gayathri DiwakarSenior Director of Investor Relations
  • Ms. Garlan Adams J.D.Chief Legal Officer & Corporate Secretary
  • Ms. Adriana Cabre M.B.A.Chief Human Resources Officer
  • Dr. Alan S. Krasner M.D.Chief Endocrinologist
  • Mr. Kevin CappsHead of Intellectual Property
  • Mr. Chris Robillard M.B.A.Chief Business Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.